United Kingdom

People: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

4:38pm BST
Change (% chg)

€3.70 (+2.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Van Rompaey, Luc 

Dr. Luc Van Rompaey serves as VP Translational Medicine at argenx SE. He is a senior R&D professional with over 18 years Life Sciences experience. Before joining argenx, Luc played a pivotal role in the development of Galapagos NV which he joined soon after its inception. He made important contributions to the successful implementation of the functional genomics platform, discovering novel osteoporosis targets that were outlicensed to Procter&Gamble, Wyeth and Eli Lilly. He was instrumental in transitioning Galapagos’ operations from target to drug discovery research. He started the JAK inhibitor research program, led the discovery and contributed to the Development of the JAK1 inhibitor GLPG0634, currently undergoing Phase II trials in rheumatoid arthritis and Crohn’s disease. He served on alliance management teams for drug discovery collaborations with GSK, Eli Lilly and Servier in the fields of osteoarthritis, immunity & inflammation, osteoporosis and oncology. Prior to joining Galapagos he performed postdoctoral research in tumor biology in St. Jude Children’s Research Hospital (US) and Leuven University (Belgium).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --